实地研究和对因子IX变异FIX-R338L的相关研究在参与者治疗费达纳古elaparvovec治疗

Debra D Pittman1, Charles Carrieri2, Holly Soares2

  • 1Rare Disease Research Unit, Pfizer Inc., Cambridge, Massachusetts, United States.

PubMed
概括

在B型血友病基因治疗中测量因子IX-R338L活性的试验显示出变异性,特别是在低水平. 优化试验选择对于准确评估费达纳科根elaparvovec治疗疗效至关重要.

相关概念视频

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...